Key facts
- Ipsen has agreed to acquire Kartos Therapeutics.
- The upfront payment for the acquisition is $450 million.
- Potential milestone payments could reach up to $1.75 billion.
- The acquisition aims to expand Ipsen's oncology pipeline.
- Kartos Therapeutics has a late-stage blood cancer treatment called navtemadlin.
Ipsen, a French biotechnology company, has announced its agreement to acquire Kartos Therapeutics, a U.S.-based biopharmaceutical company. The transaction involves an upfront payment of $450 million from Ipsen to Kartos. Furthermore, the deal includes provisions for potential milestone payments that could amount to as much as $1.75 billion, contingent upon the achievement of specific developmental or commercial targets. The primary objective of this acquisition is to expand and strengthen Ipsen's existing oncology pipeline. Specifically, Ipsen aims to incorporate Kartos's lead drug candidate, navtemadlin, which is currently in late-stage development for the treatment of blood cancer. This acquisition represents a significant strategic move for Ipsen as it seeks to bolster its presence and offerings in the competitive oncology sector.